Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy

Huang,Ying; Li,Xihan; Sha,Huizi; Zhang,Lianru; Bian,Xinyu; Han,Xiao; Liu,Baorui

doi:10.3892/or.2017.5440

Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy

Authors:
- Ying Huang
- Xihan Li
- Huizi Sha
- Lianru Zhang
- Xinyu Bian
- Xiao Han
- Baorui Liu
View Affiliations

Affiliations: The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, P.R. China, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, P.R. China, The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, P.R. China, Key Laboratory of Human Functional Genomics of Jiangsu Province, Jiangsu Diabetes Center, Nanjing Medical University, Nanjing, Jiangsu, P.R. China
Published online on: February 10, 2017 https://doi.org/10.3892/or.2017.5440
Pages: 2063-2070

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

KLA (sequence, KLAKLAKKLAKLAK) is a peptide which leads to programmed cell death by disrupting the mitochondrial membrane. However, low penetration in tumors greatly limits its application and efficacy. To develop a KLA-based cancer therapy, KLA-iRGD, a recombinant protein was constructed. It consists of the KLA peptide and iRGD (CRGDKGPDC), a tumor-homing peptide with high penetration into tumor tissue and cells. The conjugated KLA exhibits pro-apoptotic activity to prevent the growth of a tumor once it is inside the cell. Once KLA-iRGD is internalized in cultured tumor cells, via the activation of the receptor neuropilin-1, it spreads extensively throughout the mass of the tumor. The recombinant KLA-iRGD protein showed antitumor activity in vivo in mice and in vitro in tumor cell lines. Repeated treatment with KLA-iRGD greatly prevented tumor growth, resulting in a considerable reduction in tumor volume. According to our data, KLA-iRGD may serve as a potential anticancer agent with limited systemic toxicity and high selectivity for the treatment of MKN45 gastric cancer, which may lead to the enhancement of new targeted anticancer agents.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sha H, Zou Z, Xin K, Bian X, Cai X, Lu W, Chen J, Chen G, Huang L, Blair AM, et al: Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release. 200:188–200. 2015. View Article : Google Scholar : PubMed/NCBI
4	Refaat A, Abd-Rabou A and Reda A: TRAIL combinations: The new ‘trail’ for cancer therapy (Review). Oncol Lett. 7:1327–1332. 2014.PubMed/NCBI
5	Foillard S, Jin ZH, Garanger E, Boturyn D, Favrot MC, Coll JL and Dumy P: Synthesis and biological characterisation of targeted pro-apoptotic peptide. Chembiochem. 9:2326–2332. 2008. View Article : Google Scholar : PubMed/NCBI
6	Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, et al: Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 5:1032–1038. 1999. View Article : Google Scholar : PubMed/NCBI
7	Marks AJ, Cooper MS, Anderson RJ, Orchard KH, Hale G, North JM, Ganeshaguru K, Steele AJ, Mehta AB, Lowdell MW, et al: Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res. 65:2373–2377. 2005. View Article : Google Scholar : PubMed/NCBI
8	Thornberry NA, Rosen A and Nicholson DW: Control of apoptosis by proteases. Adv Pharmacol. 41:155–177. 1997. View Article : Google Scholar : PubMed/NCBI
9	Thornberry NA and Lazebnik Y: Caspases: Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
10	Chu DS, Bocek MJ, Shi J, Ta A, Ngambenjawong C, Rostomily RC and Pun SH: Multivalent display of pendant pro-apoptotic peptides increases cytotoxic activity. J Control Release. 205:155–161. 2015. View Article : Google Scholar : PubMed/NCBI
11	Javadpour MM, Juban MM, Lo WC, Bishop SM, Alberty JB, Cowell SM, Becker CL and McLaughlin ML: De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem. 39:3107–3113. 1996. View Article : Google Scholar : PubMed/NCBI
12	Hyun S, Lee S, Kim S, Jang S, Yu J and Lee Y: Apoptosis inducing, conformationally constrained, dimeric peptide analogs of KLA with submicromolar cell penetrating abilities. Biomacromolecules. 15:3746–3752. 2014. View Article : Google Scholar : PubMed/NCBI
13	Mai JC, Mi Z, Kim SH, Ng B and Robbins PD: A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 61:7709–7712. 2001.PubMed/NCBI
14	Ma JL, Wang H, Wang YL, Luo YH and Liu CB: Enhanced Peptide delivery into cells by using the synergistic effects of a cell-penetrating Peptide and a chemical drug to alter cell permeability. Mol Pharm. 12:2040–2048. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF and Ruoslahti E: Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 16:510–520. 2009. View Article : Google Scholar : PubMed/NCBI
16	Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR and Ruoslahti E: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 328:1031–1035. 2010. View Article : Google Scholar : PubMed/NCBI
17	Fu B, Long W, Zhang Y, Zhang A, Miao F, Shen Y, Pan N, Gan G, Nie F, He Y, et al: Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer. Sci Rep. 5:80292015. View Article : Google Scholar : PubMed/NCBI
18	Bryde S and de Kroon AI: Nanocapsules of platinum anticancer drugs: Development towards therapeutic use. Future Med Chem. 1:1467–1480. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Xiao W, Zhang Y, Meza L, Tseng H, Takada Y, Ames JB and Lam KS: Optimization of RGD-containing cyclic peptides against αvβ3 integrin. Mol Cancer Ther. 15:232–240. 2016. View Article : Google Scholar : PubMed/NCBI
20	Jain RK: The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 4:1–23. 1997. View Article : Google Scholar : PubMed/NCBI
21	Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, Manchul LA, Keane TJ and Hill RP: Interstitial fluid pressure in cervical carcinoma: Within tumor heterogeneity, and relation to oxygen tension. Cancer. 82:2418–2426. 1998. View Article : Google Scholar : PubMed/NCBI
22	Heldin CH, Rubin K, Pietras K and Ostman A: High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 4:806–813. 2004. View Article : Google Scholar : PubMed/NCBI
23	Li R, Xie L, Zhu Z, Liu Q, Hu Y, Jiang X, Yu L, Qian X, Guo W, Ding Y, et al: Reversion of pH-induced physiological drug resistance: A novel function of copolymeric nanoparticles. PLoS One. 6:e241722011. View Article : Google Scholar : PubMed/NCBI
24	Netti PA, Berk DA, Swartz MA, Grodzinsky AJ and Jain RK: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60:2497–2503. 2000.PubMed/NCBI
25	Davies CL, Berk DA, Pluen A and Jain RK: Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer. 86:1639–1644. 2002. View Article : Google Scholar : PubMed/NCBI
26	Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y and Jain RK: Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 9:796–800. 2003. View Article : Google Scholar : PubMed/NCBI
27	Ma X, Jia J, Cao R, Wang X and Fei H: Histidine-iridium (III) coordination-based peptide luminogenic cyclization and cyclo-RGD peptides for cancer-cell targeting. J Am Chem Soc. 136:17734–17737. 2014. View Article : Google Scholar : PubMed/NCBI
28	Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM, Mattrey RF, Verma IM and Ruoslahti E: Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci USA. 108:17450–17455. 2011. View Article : Google Scholar : PubMed/NCBI
29	Alves ID, Carré M, Montero MP, Castano S, Lecomte S, Marquant R, Lecorché P, Burlina F, Schatz C, Sagan S, et al: A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth. Biochim Biophys Acta. 1838:2087–2098. 2014. View Article : Google Scholar : PubMed/NCBI
30	Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T and Ruoslahti E: Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. 73:1352–1361. 2013. View Article : Google Scholar : PubMed/NCBI